There is a complicated relationship between abortion as such and the selective abortion of female foetuses. This dilemma is one with which the women’s movement in India has been grappling since the late 1980s. In my discussion of this dilemma, I would like to move away completely from Satyamev Jayate, the television programme, (on which a discussion has been initiated by Shohini Ghosh on kafila.org). In any case, there the...

The Government of India has formally launched the news Guidelines of the MGNAREGA based on the Mihir Shah Committee report. The news guidelines include many new works under conservation activities and it strengthens the hands of the village panchayats and gram sabhas. However, the list of works does not include the activities under the system of rice intensification (SRI) which encourages scientific method of paddy cultivation with better yield in...

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

Bench asks government to reach out to the women, think of an immediate alternative The Supreme Court on Wednesday set up a seven-member committee to look into the deplorable conditions of “widows/destitutes” living in Vrindavan and set an eight-week deadline to complete its report. The committee, headed by the chairman of the Mathura District Legal Services Authority, will prepare a list of the widows with their names, age and reasons for being...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...